A quantitative analysis of two-dimensional manually segmented transrectal ultrasound axial images in planning high dose rate brachytherapy for prostate cancer
Abstract
Background/Aim. Prostate delineation, pre-planning and catheter implantation procedures, in high-dose rate brachytherapy (HDR-BT), are commonly based on the prostate manually segmented transrectal ultrasound (TRUS) images. The aim of this study was to quantitatively analyze the consistency of prostate capsule delineation, done by a single therapist, prior to each HDR-BT fraction and the changes in the shape of the prostate capsule during HDR-BT, using two dimensional (2D) TRUS axial image. Methods. A group of 16 patients were treated at the Medical System Belgrade Brachytherapy Department with definitive HDR-BT. The total applied median dose of 52 Gy was divided into four individual fractions, each fraction being delivered 2–3 weeks apart. Real time prostate axial visualization and the manual segmentation prior to each fraction were performed using B-K Medical ultrasound. Quantitative analyses, analysis of an area and shape were applied on 2D-TRUS axial images of the prostate.
Area analyses were used to calculate the average value of the cross-sectional area of the prostate image. The parameters of the prostate shape, the fractal dimension and the circularity ratio of the prostate capsule contour were estimated at the maximum axial cross section of the prostate image. Results. The sample group consisted of four phases, each phase being performed prior to the first, second, third and fourth HDR-BT fraction, respectively. Statistical analysis showed that during HDR-BT fractions there were no significant differences in the average value of area, as well as in the maximum shape of prostate capsule. Conclusions. Quantitative analysis of TRUS axial prostate segmented images shows a successful capsule delineation in the series of manually segmented TRUS images, and the prostate maximum shape remaining unchanged during HDR-BT fractions.
References
Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Can-cer J Clin 1999; 49(1): 33−64, 1.
Acimovic M, Dabic-Stankovic K, Pejcic T, Dzamic Z, Rafailovic D, Hadzi-Djokic J. Preoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recur-rence after radical prostatectomy. J BUON 2013; 18(4): 954−60.
Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: screening, di-agnosis, and treatment of clinically localised disease. Eur Urol 2011; 59(1): 61−71.
Arsenijević T, Dabić-Stanković K, Aćimović M, Radošević-Jelić LJ. Radiotherapy in Prostate Cancer.In: Spiess P, editor. Prostate Cancer: Diagnostic and Therapeutic Advances. Rijeka, Croatia: InTech; 2011.
Mitsuzuka K, Koie T, Narita S, Kaiho Y, Yoneyama T, Tsuchiya N, et al. Pathological and oncological outcomes of elderly men with clinically localized prostate cancer. Jpn J Clin Oncol 2013; 43(12): 1238−42.
Blasko J, Radge H, Schumacher D. Transperineal percutaneous iodine-125 implantation for prostatic carcinoma using tranrec-tal ultrasound and temlate guidance. Endocuriether Hyper-therm Oncol 1987; 3: 131–9.
Blasko JC, Wallner K, Grimm PD, Ragde H. Prostate specific an-tigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma. J Urol 1995; 154(3): 1096−9.
Blasko JC, Grimm PD, Sylvester JE, Badiozamani KR, Hoak D, Ca-vanagh W. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 2000; 46(4): 839−50.
Barkati M, Williams SG, Foroudi F, Tai KH, Chander S, van Dyk S, et al. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial. Int J Radiat On-col Biol Phys 2012; 82(5): 1889−96.
Demanes DJ, Martinez AA, Ghilezan M, Hill DR, Schour L, Brandt D, et al. High-dose-rate monotherapy: safe and effective bra-chytherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2011; 81(5): 1286−92.
Grills IS, Martinez AA, Hollander M, Huang R, Goldman K, Chen PY, et al. High dose rate brachytherapy as prostate cancer mo-notherapy reduces toxicity compared to low dose rate palla-dium seeds. J Urol 2004; 171(3): 1098−104.
Hoskin P, Rojas A, Lowe G, Bryant L, Ostler P, Hughes R, et al. High-dose-rate brachytherapy alone for localized prostate can-cer in patients at moderate or high risk of biochemical recur-rence. Int J Radiat Oncol Biol Phys 2012; 82(4): 1376−84.
Rogers CL, Alder SC, Rogers RL, Hopkins SA, Platt ML, Childs LC, et al. High dose brachytherapy as monotherapy for inter-mediate risk prostate cancer. J Urol 2012; 187(1): 109−16.
Yoshioka Y, Konishi K, Sumida I, Takahashi Y, Isohashi F, Ogata T, et al. Monotherapeutic high-dose-rate brachytherapy for pros-tate cancer: five-year results of an extreme hypofractionation regimen with 54 Gy in nine fractions. Int J Radiat Oncol Biol Phys 2011; 80(2): 469−75.
Das KR. Prostate brachytherapy: HDR or seed implant. J Med Phys 2006; 31(4): 239−41.
Cosset JM, Haie-Meder C. Brachytherapy for prostate cancer: high dose rate or low-dose rate? Cancer Radiother 2005; 9(8): 610−9. (French)
King CR. LDR vs. HDR brachytherapy for localized prostate cancer: The view from radiobiological models. Brachytherapy 2002; 1(4): 219−26.
Kälkner KM, Kubicek G, Nilsson J, Lundell M, Levitt S, Nilsson S, et al. Prostate volume determination: Differential volume mea-surements comparing CT and TRUS. Radiother Oncol 2006; 81(2): 179−83.
Solhjem MC, Davis BJ, Pisansky TM, Wilson TM, Mynderse LA, Herman MG, et al. Prostate volume measurement by transrectal ultrasound and computed tomography before and after per-manent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2004; 60(3): 767−76.
Buch K, Morancy T, Kaplan I, Qureshi MM, Hirsch AE, Rofksy NM, et al. Improved dosimetry in prostate brachytherapy using high resolution contrast enhanced magnetic resonance im-aging: a feasibility study. J Contemp Brachytherapy 2015; 6(4): 337−43.
Holmes DR 3rd, Davis BJ, Goulet CC, Wilson TM, Mynderse LA, Furutani KM, et al. Shape analysis of the prostate: establishing imaging specifications for the design of a transurethral imaging device for prostate brachytherapy guidance. Brachytherapy 2014; 13(5): 465−70.
Litjens G, Toth R, van de Ven W, Hoeks C, Kerkstra S, Ginneken B, et al. Evaluation of prostate segmentation algorithms for MRI: The PROMISE12 challenge. Med Image Anal 2014; 18(2): 359−73.
Mahdavi SS, Chng N, Spadinger I, Morris WJ, Salcudean SE. Semi-automatic segmentation for prostate interventions. Med Image Anal 2011; 15(2): 226−37.
Pfengfei W, Yiguang L, Yongzhong L, Liping C. TRUS Image seg-mentation driwen by narrow band contrast pattern using shape space embedded level sets. In: Jian Y, Fang F, Changyin S, editors. Intelligent Science and Intelligent Data Engineering: Lecture Notes in Computer Science. Berlin, Heidelberg: Springer-Verlag; 2013. p. 339−46.
Pingkun Y, Sheng X, Baris T, Kruecker J. Discrete deformable model guided by partial active shape model for TRUS image segmentation. IEEE T Biomed Eng 2010; 57(5): 1158−66.
Thompson S, Delaney G, Gabriel G, Izard MA, Hruby G, Ja-gavkar R, et al. Prostate brachytherapy in New South Wales: Patterns of care study and impact of caseload on treatment quality. J Contemp Brachytherapy 2015; 6(4): 344−9.
Yamada Y, Rogers L, Demanes DJ, Morton G, Prestidge BR, Pouliot J, et al. American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy 2012; 11(1): 20−32.
Skowronek J. Low-dose-rate or high-dose-rate brachytherapy in treatment of prostate cancer - between options. J Contemp Brachytherapy 2013; 5(1): 33−41.
Milosević NT, Ristanović D, Marić DL, Rajković K. Morphology and cell classification of large neurons in the adult human den-tate nucleus: A quantitative study. Neurosci Lett 2010; 468(1): 59−63.
Ristanović D, Milosević NT, Stefanović BD, Marić DL, Rajković K. Morphology and classification of large neurons in the adult human dentate nucleus: A qualitative and quantitative analysis of 2D images. Neurosci Res 2010; 67(1): 1−7.
Milosević NT, Ristanović D, Jelinek HF, Rajković K. Quantitative analysis of dendritic morphology of the α and δ retinal gan-glion cells in the rat: A cell classification study. J Theor Biol 2009; 259(1): 142−50.
Alder H, Roessler EB. Introduction to Probability and Statistics. San Francisco, USA: WH Freeman and Co; 1972.
Rajković K, Bačić G, Ristanović D, Milošević NT. Mathematical Model of Neuronal Morphology: Prenatal Development of the Human Dentate Nucleus. Biomed Res Int 2014; 2014: 1−8.
Riffenburgh RH. Statistics in Medicine. London, UK: Academic Press; 1999.
Di Ieva A, Grizzi F, Sherif C, Matula C, Tschabitscher M. An-gioarchitectural heterogeneity in human glioblastoma multi-forme: A fractal-based histopathological assessment. Micro-vasc Res 2011; 81(2): 222−30.
Lopes R, Betrouni N. Fractal and multifractal analysis: A review. Med Image Anal 2009; 13(4): 634−49.
Sanguineti G, Marcenaro M, Franzone P, Foppiano F, Vitale V. Neoadjuvant androgen deprivation and prostate gland shrin-kage during conformal radiotherapy. Radiother Oncol 2003; 66(2): 151−7.
Budiharto T, Slagmolen P, Hermans J, Maes F, Verstraete J, Heuvel FV, et al. A semi-automated 2D/3D marker-based registration algorithm modelling prostate shrinkage during radiotherapy for prostate cancer. Radiother Oncol 2009; 90(3): 331−6.